PA-NEURAPTIVE
17.11.2022 14:15:33 CET | Business Wire | Press release
Neuraptive Therapeutics, Inc., a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by nerve injuries, announced the appointment of industry R&D pioneer Robert (Bob) R. Ruffolo, Jr., Ph.D. to the company’s Board of Directors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221117005443/en/
Robert R. Ruffolo, Ph.D. (Photo: Business Wire)
“On behalf of the Neuraptive Board and its directors, we are excited to welcome Bob to the board,” said Robert Radie, chairman, and chief executive officer of Neuraptive. “His extensive experience in drug research and development is a great addition to the Neuraptive board at this important time. We are fortunate to have attracted such an accomplished leader in our industry which speaks to the promise and potential of the work we are doing to transform the treatment of peripheral nerve injuries."
Dr. Ruffolo has over 40 years of research and development experience and is currently the Chairman of Aragen Biosciences, Inc. and Managing Director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries. Dr. Ruffolo is the retired President of Research and Development of Wyeth Pharmaceuticals, and Corporate Senior Vice President of the Wyeth Corporation (now Pfizer). He managed an R&D organization of 9,000 scientists with an annual budget in excess of $5 billion. Prior to Wyeth, Dr. Ruffolo held executive roles at SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) and Lilly Research Laboratories. He earned his Ph.D. in Pharmacology and his B.S. in Pharmacy from The Ohio State University.
About Neuraptive
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Philadelphia, PA. For more information, see www.neuraptive.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005443/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Promega Unveils Cellular Target Engagement Technology Aimed at Expanding the Druggable Proteome at SLAS 20269.2.2026 13:00:00 CET | Press release
TarSeer™ BRETSA™ Target Engagement System enables studies for difficult proteins early in drug discovery Promega Corporation is launching a new live-cell target engagement platform that could close a long-standing gap between biochemical and cellular assays for understudied or difficult-to-interrogate proteins. The TarSeer™ BRETSA™ Target Engagement System is a novel bioluminescence resonance energy transfer-based shift assay for detecting ligand-protein interactions in intact cells using protein denaturation. It gives drug discovery researchers early, target-specific cellular insights by validating weak or early chemical matter and expanding the targets accessible in live-cell drug discovery workflows. The technology will be debuted at the Society for Laboratory Automation and Screening (SLAS) International Conference and Exhibition in Boston, February 7-11, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260206015371/
Eurofins Viracor BioPharma Expands Bioanalytical Capabilities9.2.2026 13:00:00 CET | Press release
Eurofins Viracor BioPharma Services, a long‑standing and trusted partner for clinical trial testing solutions with deep expertise in specialty biomarkers and molecular assays, announces a significant expansion of its service portfolio with the addition of enhanced bioanalytical testing capabilities. These new services are fully aligned with Good Laboratory Practices (GLP) and Good Clinical Practices (GCP), enabling the company to enhance support of biopharmaceutical development programs with greater scientific breadth throughout the drug development workflow. This strategic advancement follows the successful relocation and integration of Eurofins Pharma Bioanalytics Services from St. Charles, Missouri, into Eurofins Viracor BioPharma’s purpose‑built, eleven‑acre facility in Lenexa, Kansas. The bioanalytical organization brings more than two decades of specialized experience in pharmacokinetics, immunogenicity, and biomarker testing. By combining both laboratories’ strengths, Eurofins V
HKTDC to Host World’s Largest One-Stop Jewellery Marketplace9.2.2026 11:37:00 CET | Press release
New Hard Pure Gold Pavilion showcases breakthrough gold technologies Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one‑stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld‑Expo, featuring a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre, showcasing finished jewellery pieces. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260207153040/en/ Hong Kong International Jewellery Show and Hong Kong International Diamond, Gem & Pearl Show Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with nearly 70% coming
FlexTrade Integrates CME Group’s FX Spot+ and EBS Market Offerings for Enhanced FX Trading9.2.2026 11:30:00 CET | Press release
The initiative will see FlexTrade FX clients seamlessly access CME Group’s primary FX markets within FlexFX. FlexTrade Systems(@FlexTrade), a global leader in multi-asset execution and order management systems, today announced an integration with CME Group’s EBS Market central limit order book (CLOB) and its FX Spot+ platform.The move is designed to diversify and deepen the sources of actionable liquidity available to FlexTrade’s FlexFX users through an integration into CME Group's substantial liquidity pools for spots via FX Spot+. Providing firm, anonymous liquidity and no last-look pricing, EBS Market is a venue for both large market participants in search of FX liquidity in an all-to-all CLOB, and for market-making banks hedging FX risk. FX Spot+ further enhances spot liquidity with Futures liquidity from CME Group. This partnership is integral in helping firms further expand FX liquidity and take advantage of global opportunity. Mutual clients of FlexTrade and CME Group can integr
Clearwater Analytics Debuts Transparent Risk Platform for Power and Gas Markets at E-world 20269.2.2026 09:00:00 CET | Press release
CWAN Power and Gas breaks industry reliance on black-box systems as energy transition drives trading opportunity At E-world Energy & Water 2026, Clearwater Analytics (NYSE: CWAN) will debut CWAN Power and Gas, new risk management capabilities within Beacon by CWAN designed to end the industry’s reliance on black-box systems. With transparent methodologies and source-code visibility, the platform lets trading teams validate and customize calculations for complex power and gas instruments in real time. Visit Booth #5A118 in Hall 5 for live demonstrations. Renewables growth, liquefied natural gas flows, and shifting macroeconomic conditions are reshaping power markets and increasing both volatility and opportunity. Yet many trading firms remain constrained by legacy risk platforms that limit model visibility, customization, and speed-to-market. CWAN Power and Gas removes those constraints by making every calculation transparent, configurable, and auditable in real time—supporting complex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom